2023
The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease
Jirapinyo P, Thompson C, Garcia-Tsao G, Zucker S, Ryou M. The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Endoscopy 2023, 56: 56-62. PMID: 37532114, DOI: 10.1055/a-2146-8857.Peer-Reviewed Original ResearchMeSH KeywordsHumansLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseasePilot ProjectsProspective StudiesTreatment OutcomeWeight LossConceptsNonalcoholic fatty liver diseaseEndoscopic gastric plicationAdvanced chronic liver diseaseFatty liver diseasePortosystemic pressure gradientChronic liver diseaseLiver diseaseTotal weight lossGastric plicationNoninvasive testsBaseline median body-mass indexMedian body mass indexPercent total weight lossWeight lossProportion of patientsProspective pilot studyBody mass indexLiver stiffness measurementWeight loss proceduresGoal of therapyHepatic decompensationSecondary outcomesPrimary outcomeMass indexPatientsUpdate in the Treatment of the Complications of Cirrhosis
Abraldes J, Caraceni P, Ghabril M, Garcia-Tsao G. Update in the Treatment of the Complications of Cirrhosis. Clinical Gastroenterology And Hepatology 2023, 21: 2100-2109. PMID: 36972759, PMCID: PMC11097249, DOI: 10.1016/j.cgh.2023.03.019.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTransjugular intrahepatic portosystemic shuntVariceal hemorrhageHepatic encephalopathyPre-emptive transjugular intrahepatic portosystemic shuntsAcute variceal hemorrhageCombination of terlipressinAcute kidney injuryComplications of cirrhosisSecond-line treatmentSignificant portal hypertensionFirst-line treatmentLeast common causePrognosis of patientsOrnithine L-aspartatePresence of varicesIntrahepatic portosystemic shuntStandard of careQuality of lifeCyanoacrylate injectionHepatorenal syndromeUncomplicated ascitesKidney injuryPortal hypertensionRefractory ascitesAlbumin use
2020
Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes
Montalvo‐Gordon I, Chi‐Cervera L, García‐Tsao G. Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology 2020, 72: 1880-1882. PMID: 32294260, DOI: 10.1002/hep.31270.Peer-Reviewed Original Research
2015
High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease
Reddy KR, O'Leary JG, Kamath PS, Fallon MB, Biggins SW, Wong F, Patton HM, Garcia‐Tsao G, Subramanian RM, Thacker LR, Bajaj JS, Disease F. High risk of delisting or death in liver transplant candidates following infections: Results from the North American consortium for the study of end‐stage liver disease. Liver Transplantation 2015, 21: 881-888. PMID: 25845966, DOI: 10.1002/lt.24139.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver transplantationOrgan failureNorth American ConsortiumLiver diseaseUnderwent transplantationMELD scoreMedian ageEnd-stage liver disease (MELD) scoreTertiary-care hepatology centersAmerican ConsortiumExtrahepatic organ failureMean MELD scoreLiver Disease scoreLiver transplant candidatesPatients' median ageHepatitis C virusType of infectionPrevention of infectionHepatology centersTransplant candidatesCirculatory failureC virusInfected patientsHigh risk
2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volume
2008
Hepatic Vascular Malformations in Hereditary Hemorrhagic Telangiectasia
Khalid S, Garcia-Tsao G. Hepatic Vascular Malformations in Hereditary Hemorrhagic Telangiectasia. Seminars In Liver Disease 2008, 28: 247-258. PMID: 18814078, DOI: 10.1055/s-0028-1085093.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHereditary hemorrhagic telangiectasiaHepatic arteryVascular malformationsHepatic veinPortal veinHemorrhagic telangiectasiaHigh-output cardiac failureAbnormal vascular communicationAggressive medical therapyHepatic vascular malformationsPredominant clinical presentationCommon hepatic arteryNodular regenerative hyperplasiaIntensive medical treatmentFocal nodular hyperplasiaAutosomal dominant vascular disorderAbdominal anginaBiliary ischemiaLiver transplantationPortal hypertensionRegenerative hyperplasiaSymptomatic patientsCommon presentationMedical therapyCardiac failurePrediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Mayo MJ, Parkes J, Adams‐Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia‐Tsao G, Barnes D, Rosenberg WM. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008, 48: 1549-1557. PMID: 18846542, PMCID: PMC2597274, DOI: 10.1002/hep.22517.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum fibrosis markersBiliary cirrhosisLiver biopsyClinical progressionFibrosis markersLiver fibrosisPrognostic informationPrognostic performanceSerial liver biopsy specimensEnd-stage liver diseaseLong-term prognostic informationLiver-related deathPositive antimitochondrial antibodyMayo risk scoreEvent-free survivalAppropriate clinical settingSerum hyaluronic acidEnhanced liver fibrosisLiver biopsy specimensAccurate noninvasive measureFibrosis algorithmsPBC subjectsVariceal bleedBiopsy complicationsA Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.Peer-Reviewed Original ResearchMeSH KeywordsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesGermanyHepatorenal SyndromeHumansInjections, IntravenousKidney Function TestsLypressinMaleMiddle AgedProspective StudiesRussiaSeverity of Illness IndexShock, SepticSurvival RateTerlipressinTreatment OutcomeUnited StatesVasoconstrictor AgentsConceptsHRS type 1Type 1 HRSSCr levelsTreatment successDay 14Type 1Total adverse event rateType 1 hepatorenal syndromePlacebo-controlled clinical trialSafety of terlipressinTrial of terlipressinAdvanced liver diseaseFunctional renal failureNonfatal myocardial infarctionSerum creatinine levelsTransplantation-free survivalAdverse event ratesSyndrome type 1Arterial vasoconstrictorHepatorenal syndromeHRS reversalCreatinine levelsRenal failureRenal functionLiver disease
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsHepatic VeinsHepatitis C, ChronicHumansTreatment OutcomeVenous PressureConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse
1999
Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements
Steinlauf A, Garcia‐Tsao G, Zakko M, Dickey K, Gupta T, Groszmann R. Low‐dose midazolam sedation: An option for patients undergoing serial hepatic venous pressure measurements. Hepatology 1999, 29: 1070-1073. PMID: 10094948, DOI: 10.1002/hep.510290421.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHepatic venous pressure measurementsWedged hepatic venous pressureFree hepatic venous pressureVenous pressure measurementsHepatic venous pressurePortal hypertensionVenous pressureSerial measurementsPatient comfortVenous pressure gradientDoses of midazolamDouble-blind studyDose of midazolamHigh-dose midazolamEffects of midazolamEffects of sedativesPortal pressure measurementsPressure measurementsCompensated cirrhosisVariceal hemorrhageCirrhotic patientsPharmacological therapyMidazolam sedationPrognostic index